Will Faeth Therapeutics stock go up?

According to Danelfin AI, Faeth Therapeutics has today an AI Score of 2/10 (Strong Sell rating), because its probability of beating the market in 3 months (43.88%) is -6.94% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Faeth Therapeutics stock?

The Faeth Therapeutics target price is $22.94 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Faeth Therapeutics stock right now?

Faeth Therapeutics has today a Strong Sell rating (AI Score 2/10), according to Danelfin AI. Its probability of beating the market in 3 months (43.88%) is -6.94% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis.

Is Faeth Therapeutics undervalued right now?

Based on analysts, the average price target downside for Faeth Therapeutics is 0.00% (1Y). According to Danelfin AI, Faeth Therapeutics has today an AI Score of 2/10 (Strong Sell Rating).

What was the price range of Faeth Therapeutics stock over the past 12 months?

The Faeth Therapeutics stock price range over the past 12 months has been $6.8 - $35.07.

What is going on with Faeth Therapeutics stock in the last 3 months?

The Faeth Therapeutics stock performance in the last quarter has been -34.06%.

Does Faeth Therapeutics offer dividend payments?

No, Faeth Therapeutics does not currently pay dividends.

What is the current market capitalization of Faeth Therapeutics?

Faeth Therapeutics's market cap is $590.85M, as of 2026-07-03 08:00.

Sensei Biotherapeutics Inc (FTH) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

FTH AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Earnings Quality+1.60%
Stability and reliability of reported earnings
Valuation+1.30%
How the stock is priced relative to its fundamentals
Sentiment+0.01%
How analysts and the market view the stock

Volatility-4.27%
How much the stock price tends to fluctuate
Momentum-3.92%
Direction and strength of recent price movements
Size & Liquidity-0.96%
Company size and trading liquidity
Financial Strength-0.43%
Balance sheet strength and financial resilience
Growth-0.27%
Expected pace of revenue and earnings expansion

FTH probability advantage of beating the market (3M):

-6.94%

AI Score

Strong Sell

Faeth Therapeutics (FTH) has an AI Score of 2/10 (Strong Sell) because, according to an overall analysis, it has a probability advantage of -6.94% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of FTH (43.88%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
FTH probability advantage of beating the market (3M)-6.94%
FTH probability of beating the market (3M)43.88%

FTH probability advantage of beating the market (3M): -6.94%

The AI-powered overall analysis of Faeth Therapeutics (FTH) is based on the 27 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of FTH:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Operating Cash Flow (Qtr Discrete)	-10.73		+1.60%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+1.45%
Technical	Chart Pattern (120d)	figure_123	N/A	-1.43%
Technical	Maximum Volatility	23.76%		-1.12%
Technical	Normalized Average True Range (50d)	12.81%		-1.05%
Fundamental	Beginning Cash (Millions)	8.67		-0.96%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.93%
Technical	ATR (90d Volatility)	2.53		-0.87%
Technical	ATR (14d Volatility)	3.38		-0.70%
Technical	Technicals Impact (Long Tail)	-	N/A	-0.70%
Technical	Upgrade to unlock			+0.66%
Sentiment	Upgrade to unlock			+0.66%
Technical	Upgrade to unlock			-0.63%
Fundamental	Upgrade to unlock			+0.60%
Sentiment	Upgrade to unlock			-0.57%

Rest of Alpha Signals: -2.95%

FTH probability advantage of beating the market (3M)Total:-6.94%
FTH AI Score

Significant changes Vs previous day

FTH Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$22.94
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

FTH Proven Sell Signal & Price Forecast

This is the price chart for FTH from January 2, 2026 until today. The chart indicates, in red, the 12 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

FTH Average Past Performance & Loss Rate

Three months after its 10 Sell signals since July 2026, FTH had an average performance of xxxxx and a xxxxxxx Loss rate (negative performance).

10 Past FTH Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				0.00%
Average Alpha				0.00%
Loss Rate (% Negative Perf.)				100.00%
% Negative Alpha				100.00%

FTH Frequently Asked Questions

Will Faeth Therapeutics stock go up?
According to Danelfin AI, Faeth Therapeutics has today an AI Score of 2/10 (Strong Sell rating), because its probability of beating the market in 3 months (43.88%) is -6.94% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Faeth Therapeutics stock?
Is it a good time to buy, sell, or hold Faeth Therapeutics stock right now?
Is Faeth Therapeutics undervalued right now?
What was the price range of Faeth Therapeutics stock over the past 12 months?
What is going on with Faeth Therapeutics stock in the last 3 months?
Does Faeth Therapeutics offer dividend payments?
What is the current market capitalization of Faeth Therapeutics?

Sensei Biotherapeutics Inc Company Profile

Faeth Therapeutics Inc (FTH) develops precision oncology treatments that integrate drug therapies with nutritional science. The company focuses on metabolic interventions to enhance the efficacy of cancer treatments for patients. It aims to disrupt cancer cell metabolism by combining targeted therapeutics with specific dietary regimens, thereby creating a hostile environment for tumor growth.

The company researches and develops novel therapeutic candidates. These candidates are designed to target specific metabolic vulnerabilities within various cancer types, including those resistant to conventional therapies. Its drug discovery efforts focus on identifying small molecules that can selectively inhibit pathways crucial for tumor growth and survival. This approach seeks to create an environment where cancer cells are deprived of essential nutrients or metabolic resources, making them more susceptible to treatment.

Faeth Therapeutics also integrates dietary interventions into its comprehensive therapeutic strategies. It develops personalized nutritional plans intended to complement its drug treatments, optimizing their impact. This integrated approach aims to modulate the tumor microenvironment and improve the overall effectiveness of therapies by altering nutrient availability. The company utilizes a proprietary computational platform to identify and validate these combined drug-diet strategies, optimizing patient outcomes. This platform helps in understanding the complex interplay between diet, metabolism, and cancer progression, guiding the development of novel treatment protocols.

The company's primary focus is on advancing its therapeutic candidates through rigorous preclinical and clinical development stages. It collaborates with leading research institutions and clinical sites to conduct studies evaluating the safety and efficacy of its combined drug-diet regimens. Faeth Therapeutics aims to bring these innovative oncology solutions to patients suffering from various cancers, addressing unmet medical needs. Its pipeline targets multiple tumor types, leveraging its unique metabolic approach.

Faeth Therapeutics primarily serves the healthcare sector, including medical professionals, researchers, and ultimately, patients requiring advanced cancer care. Its distribution model involves direct engagement with clinical trial sites and potential future partnerships with larger pharmaceutical companies for broader commercialization. The company generates revenue through drug development milestones, potential licensing agreements, and future product sales. Its go-to-market strategy involves direct clinical development and potential channel partnerships, with a global presence in research and development.

Sector:
Country:United States
Industry:
Address:701 Tillery Street #12 #1010, Austin
Employees:29
Website:senseibio.com

Pros

Differentiated phage-based immunotherapy platform technology

Addressing high unmet medical needs in oncology

Potential for cost-effective biologic manufacturing scalability

Broad applicability of platform across multiple indications

Proprietary intellectual property protecting core technology

Cons

High clinical development failure rates for novel therapies

Intense competitive landscape in cancer immunotherapy

Substantial capital requirements for drug research and development

Complex regulatory pathway for first-in-class biologic modalities

Pipeline dependency on single platform technology validation

Company	AI Score	Compare
SMMTSummit Therapeutics Inc
SNTISenti Biosciences Inc
IKTInhibikase Therapeutics Inc
COGTCogent Biosciences Inc
VORVor Biopharma Inc

Company	AI Score	Compare
SMMTSummit Therapeutics Inc
SNTISenti Biosciences Inc
IKTInhibikase Therapeutics Inc
COGTCogent Biosciences Inc
VORVor Biopharma Inc

FTH Stock AI Analysis